8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in
children and adolescents with heterozygous familial hypercholesterolemia
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.